ValuEngine lowered shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) from a sell rating to a strong sell rating in a report released on Friday morning, ValuEngine reports.
Separately, Morgan Stanley began coverage on ASTELLAS PHARMA/ADR in a research note on Thursday, January 23rd. They issued an overweight rating for the company.
Shares of OTCMKTS:ALPMY opened at $17.62 on Friday. ASTELLAS PHARMA/ADR has a 52-week low of $12.77 and a 52-week high of $17.77. The stock has a market cap of $33.28 billion, a price-to-earnings ratio of 16.62 and a beta of 0.77. The business has a 50-day moving average price of $17.18 and a 200-day moving average price of $15.60.
About ASTELLAS PHARMA/ADR
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.
See Also: What are municipal bonds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.